Glucosamine, a supplement commonly taken for joint discomfort, was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia in a large health-record analysis. Researchers said the preliminary findings do not prove causation, but experiments involving mice and human Alzheimer’s brain tissue identified a possible metabolic mechanism that warrants clinical trials.
What did the health-record study find?
Researchers at the University of Florida analyzed deidentified UF Health records collected from 2012 to 2024. The study included 1,896 people with Alzheimer’s disease and related dementias and 2,750 people with mild cognitive impairment, or MCI.
MCI describes measurable memory or thinking difficulties greater than expected with normal aging, though they do not necessarily interfere substantially with everyday life. In both groups, 8% of patients reported using glucosamine.
After accounting for age, sex and demographics, the researchers found that glucosamine use was associated with a 25% higher likelihood that MCI would progress to dementia. Among people who already had Alzheimer’s disease and related dementias, glucosamine use was also associated with a 25% higher mortality risk during a defined period.
The researchers did not observe the mortality association in the MCI group. This difference suggests that glucosamine may have a stronger effect after dementia is established, but the study does not establish that it causes either progression or death.
UF Health reported that about 7 million people in the United States are living with Alzheimer’s, with millions more living with related dementias such as Lewy body or frontotemporal dementia. Glucosamine is sold without a prescription and is especially popular among older adults who take it for joint discomfort and joint health.
What did the experiments show?
The study, published in Nature Metabolism, also examined a metabolic pathway involving the attachment of sugar structures to proteins. This process is part of normal cell biology, but the researchers found signs that it was excessively active in Alzheimer’s disease.
In genetically modified mice, glucosamine significantly increased the attachment of sugar residues to proteins inside cells. The treated mice also developed worse deficits in social memory, which refers to memory of recognition, than the other animals.
When the researchers used a chemical treatment to suppress the sugar-attachment process, memory performance improved. This suggested that excessive sugar tagging may have played a direct role in the memory problems seen in the animals rather than occurring only alongside them.
Human brain specimens from people with Alzheimer’s disease showed significantly more sugar attachment than tissue from normal controls. Together, the record analysis, mouse experiments and tissue findings suggest that abnormal metabolism may contribute to the disease process instead of occurring only as a consequence of Alzheimer’s.
How might glucosamine interact with the Alzheimer’s brain?
Glucosamine is a naturally occurring, sugar-related molecule that can cross the blood-brain barrier. Once inside the brain, it can enter biochemical pathways that build complex sugar structures and attach them to proteins.
The researchers used a spatial technology developed in the laboratory of senior author Ramon Sun to examine thousands of molecules produced when the body breaks down food or drugs. Their focus was on whether glucosamine might affect metabolic pathways differently in a healthy brain and a brain affected by Alzheimer’s.
The Alzheimer’s brain appeared particularly vulnerable to the sugar-attachment pathway. This biological difference could explain why the same molecule might affect people differently, including those with and without established Alzheimer’s disease or related dementias.
Many proteins require sugar tags to fold and function correctly. The findings suggest that the system is overactive in Alzheimer’s disease and that the brain adds more sugar structures than normal.
Ramon Sun, Ph.D., said the results suggest that altered metabolism is a significant contributor to Alzheimer’s progression. Addressing a metabolic defect could therefore become an important complement to approaches focused on plaques and tangles, the two best-known features of Alzheimer’s disease. Plaques are deposits of the protein amyloid beta between brain cells, while tangles are twisted forms of the tau protein inside neurons.
What does this mean for everyday supplement choices?
The findings give people with cognitive impairment or dementia a specific question to discuss with a clinician, but they do not provide evidence for a blanket recommendation to stop glucosamine.
Because the health-record analysis was observational, people who used glucosamine may have differed in other ways from those who did not. Those differences could help explain some of the association. The study also combined records with experiments that cannot establish the same causal relationship in people.
A controlled human clinical trial would be needed to determine whether glucosamine directly accelerates Alzheimer’s progression and which patients, if any, are most vulnerable.
What to do now
-
Tell a clinician if you have mild cognitive impairment or dementia and take glucosamine, including the product and the reason for using it.
-
Ask a clinician to review all supplements and over-counter medicines rather than stopping or changing treatment on your own.
-
Be cautious about assuming that the association proves glucosamine causes progression, since the researchers said human clinical trials are still needed.
-
Watch for the specific study questions about memory and Alzheimer’s progression, and discuss any changes in cognition with a healthcare professional.
FAQ
Does glucosamine cause Alzheimer’s disease to progress faster?
The study found an association, not proof of causation. Researchers said a controlled human clinical trial is needed to determine whether glucosamine directly accelerates Alzheimer’s progression and which patients may be most vulnerable.
What was the difference between MCI and Alzheimer’s-related dementia?
Mild cognitive impairment describes measurable memory or thinking difficulties greater than expected with normal aging, but it does not necessarily interfere substantially with everyday life. The health-record analysis studied people with either MCI or Alzheimer’s disease and related dementias.
Why might glucosamine affect an Alzheimer’s brain differently?
Glucosamine can enter the brain and participate in pathways that attach sugar structures to proteins. The researchers found that this sugar-attachment process was more active in Alzheimer’s disease and may be related to disease progression. Commercial glucosamine can be produced from materials including shellfish shells or corn, and its effects may depend on the biological environment in which it acts.
